Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Osborne, C K.; Bardou, V.; Hopp, T. A; Chamness, G. C; Hilsenbeck, S. G; Fuqua, S. A W; Wong, J.; Allred, D C.; Clark, G. M; and Schiff, R. Journal of the National Cancer Institute, 95(5):353–61, mar, 2003.
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. [link]Paper  doi  bibtex   
@article{Osborne2003,
    author = {Osborne, C Kent and Bardou, Valerie and Hopp, Torsten A and Chamness, Gary C and Hilsenbeck, Susan G and Fuqua, Suzanne A W and Wong, Jiemin and Allred, D Craig and Clark, Gary M and Schiff, Rachel},
    doi = {10.1017/CBO9781107415324.004},
    isbn = {9788578110796},
    issn = {0027-8874},
    journal = {Journal of the National Cancer Institute},
    month = {mar},
    number = {5},
    pages = {353--61},
    pmid = {12618500},
    title = {{Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.}},
    url = {http://www.ncbi.nlm.nih.gov/pubmed/12618500},
    volume = {95},
    year = {2003}
}
Downloads: 0